IONIS PHARMACEUTICALS INC (IONS)
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
📈 **POSITIVE** • Medium confidence analysis (71%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business